41 related articles for article (PubMed ID: 11949838)
21. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Duffy MJ
Biochem Soc Trans; 2002 Apr; 30(2):207-10. PubMed ID: 12023852
[TBL] [Abstract][Full Text] [Related]
22. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Mengele K; Napieralski R; Magdolen V; Reuning U; Gkazepis A; Sweep F; Brünner N; Foekens J; Harbeck N; Schmitt M
Expert Rev Mol Diagn; 2010 Oct; 10(7):947-62. PubMed ID: 20964613
[TBL] [Abstract][Full Text] [Related]
24. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Schmitt M; Harbeck N; Brünner N; Jänicke F; Meisner C; Mühlenweg B; Jansen H; Dorn J; Nitz U; Kantelhardt EJ; Thomssen C
Expert Rev Mol Diagn; 2011 Jul; 11(6):617-34. PubMed ID: 21745015
[TBL] [Abstract][Full Text] [Related]
25. [Role of plasminogen activator inhibitor type 1 in tumor angiogenesis].
Bajou K; Devy L; Masson V; Albert V; Frankenne F; Noël A; Foidart JM
Therapie; 2001; 56(5):465-72. PubMed ID: 11806282
[TBL] [Abstract][Full Text] [Related]
26. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye.
Kwaan HC; Mazar AP; McMahon BJ
Semin Thromb Hemost; 2013 Jun; 39(4):382-91. PubMed ID: 23532574
[TBL] [Abstract][Full Text] [Related]
27. Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review).
Jankun J; Al-Senaidy A; Skrzypczak-Jankun E
Int J Mol Med; 2012 Jan; 29(1):3-11. PubMed ID: 21993838
[TBL] [Abstract][Full Text] [Related]
28. [Urokinase plasminogen activation system and its role in cancer progression].
Błasiak J; Smolarz B; Piestrzeniewicz D
Postepy Biochem; 1999; 45(1):42-50. PubMed ID: 10480164
[No Abstract] [Full Text] [Related]
29. Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy.
Scott-Coombes DM; Whawell SA; Vipond MN; Crnojevic L; Thompson JN
Gut; 1993 Aug; 34(8):1120-2. PubMed ID: 8174965
[TBL] [Abstract][Full Text] [Related]
30. Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma.
Lee JA; Cochran BJ; Lobov S; Ranson M
Semin Thromb Hemost; 2011 Jun; 37(4):395-407. PubMed ID: 21805446
[TBL] [Abstract][Full Text] [Related]
31. Yin and yang of the plasminogen activator inhibitor.
Jankun J; Skrzypczak-Jankun E
Pol Arch Med Wewn; 2009 Jun; 119(6):410-7. PubMed ID: 19694224
[TBL] [Abstract][Full Text] [Related]
32. PZP and PAI-2: Structurally-diverse, functionally similar pregnancy proteins?
Wyatt AR; Cater JH; Ranson M
Int J Biochem Cell Biol; 2016 Oct; 79():113-117. PubMed ID: 27554634
[TBL] [Abstract][Full Text] [Related]
33. The role of SerpinB2 in immunity.
Schroder WA; Major L; Suhrbier A
Crit Rev Immunol; 2011; 31(1):15-30. PubMed ID: 21395508
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen activator inhibitor type-2. A spontaneously polymerizing serpin that exists in two topological forms.
Ny T; Mikus P
Adv Exp Med Biol; 1997; 425():123-30. PubMed ID: 9433495
[No Abstract] [Full Text] [Related]
35. Proteases in gastrointestinal neoplastic diseases.
Herszényi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Foschia F; Tulassay Z; Naccarato R; Farinati F
Clin Chim Acta; 2000 Feb; 291(2):171-87. PubMed ID: 10675722
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
[TBL] [Abstract][Full Text] [Related]
37. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
[TBL] [Abstract][Full Text] [Related]
38. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
39. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].
Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z
Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
